Form 4: Merus CFO Disposes Options in Genmab Tender Offer

Merus N.V.'s Chief Financial Officer, Gregory D. Perry, disposed of all his share options on December 12, 2025, as part of Genmab's tender offer to acquire the company for $97.00 per share.

Summary

• Gregory D. Perry, Chief Financial Officer and PFO of Merus N.V. (MRUS), disposed of all his share options.
• The disposal occurred on December 12, 2025, coinciding with the acceptance time of a tender offer.
• Genmab Holding II B.V., a subsidiary of Genmab A/S, commenced a tender offer to acquire all issued and outstanding common shares of Merus N.V.
• The tender offer consideration was a cash payment of $97.00 per share.
• The share options were cancelled pursuant to the transaction agreement, with Mr. Perry receiving a cash payment equal to the difference between the $97.00 offer consideration and the option's exercise price, multiplied by the number of shares underlying the option.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a tender offer, leading to the acquisition of Merus N.V. by Genmab. This event allowed the CFO to monetize his share options and provided a cash exit for tendering shareholders, indicating a definitive and positive outcome for those involved in the transaction.

Positives

• The Chief Financial Officer realized value from his share options through a cash payment as part of the acquisition.
• Shareholders who tendered their shares received a cash payment of $97.00 per share, providing a clear exit strategy and liquidity.

Negatives

• Merus N.V. is being acquired, indicating it will cease to be an independent publicly traded entity.

Future Outlook

The filing indicates the successful completion of a tender offer, leading to the acquisition of Merus N.V. by Genmab. The Offer Consideration is expected to be paid as soon as practicable following the Acceptance Time, signifying the final stages of Merus N.V.'s transition to a subsidiary of Genmab.

Industry Context

This transaction represents a strategic acquisition within the biotechnology and pharmaceutical industry, where larger companies often acquire smaller firms to expand their pipeline, technology, or market presence. The tender offer mechanism is a common method for such corporate takeovers.

Comparison to Industry Standards

• The tender offer process for acquiring Merus N.V. by Genmab is a standard corporate action in the M&A landscape, particularly within the life sciences sector.
• The cash consideration of $97.00 per share provides a definitive valuation for Merus N.V. at the time of acquisition, which can be benchmarked against other biotech acquisitions based on factors like pipeline stage, therapeutic area, and market capitalization, though specific comparable deals are not detailed in this filing.

Stakeholder Impact

• Shareholders: Received $97.00 per share in cash for their tendered shares.
• Employees (including CFO): Share options were cancelled for cash, indicating a change in the company's ownership and potentially future employment structure.
• Company (Merus N.V.): Will become a wholly-owned subsidiary of Genmab, ceasing independent operations.

Next Steps

• Payment of the Offer Consideration of $97.00 per share to tendering shareholders as soon as practicable following the Acceptance Time.

Key Dates

Recommendation

The filing details the successful completion of a tender offer by Genmab to acquire Merus N.V. for $97.00 per share in cash. For shareholders, this represents a definitive exit at a fixed price. Therefore, a 'sell' recommendation is appropriate for those who have not yet tendered their shares or are considering their position post-tender, as the acquisition price is now established.

Keywords

Merus N.V., MRUS, Genmab, Tender Offer, Acquisition, Share Options, Insider Transaction, Form 4, CFO